Hewlett Packard’s (HPQ) earnings guidance provided at the analyst meeting for fiscal 2010 was in-line with the Zacks Consensus Estimate of $4.26 per share. The company expects revenue of approximately $117.0 – $118.0 billion, up approximately 3.0% to 5.0% from 2009 estimated revenue. GAAP earnings per share are expected to be in the range of $3.60 – $3.70, a growth of 17% to 20% from 2009 estimated earnings, while non-GAAP earnings per share are expected to be in the $4.20 – $4.30 range. H-P also said the projections were conservative and could easily exceed the company’s forecast. H-P’s guidance validates that the IT industry is expected to return to growth and technology spending will rebound in 2010. Moreover, H-P sees a recovery in its PC business, which will help the company grow its top line as its PC division contributes nearly a third of overall sales....

Nutra Pharma has announced their intention to begin the registration for their over-the-counter pain reliever in both Canada and Europe. Currently, the company is marketing a similar product, Cobroxin, within the United States. Cobroxin is used for the treatment of moderate to severe (Stage 2) chronic pain.

According to the North American Chronic Pain Association of Canada, it is estimated that 18% of Canadians suffer from severe chronic pain. Additionally, the Pain in Europe report, which is the largest European survey of chronic pain sufferers, reports that chronic pain effects one in five adults across Europe.

Dr. Paul Redi, CEO of ReceptoPharm, stated, “We have already started in-depth conversations with regulatory specialists with the intent to begin the registration of our over-the-counter pain reliever in Canada and Europe. We are confident that our pain reliever can be successfully registered in the near term based on the existing regulatory requirements in those

...